|
Norton Neuroscience Institute is committed to advancing the fields of neurology and neurosurgery through research and clinical trials. The renowned neurosurgeons, neurologists and clinicians with Norton Neuroscience Institute are well-respected for their research. Our clinicians regularly participate in studies and publish their research and treatment findings. In return, patients of Norton Neuroscience Institute benefit from research and cutting-edge treatment not available elsewhere in our region. Through clinical studies and unique research partnerships, Norton Neuroscience Institute is dedicated to improving patient care, outcomes and quality of life.
For more information about our MS trials, call (502) 899-6782.
Clinical Trials
Title: ACCLAIM: A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-Remitting Multiple Sclerosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Robert S. Tillett Jr., M.D., MS certified specialist
Purpose: The ACCLAIM study is testing whether the medication Abatacept can be of benefit to patients with relapsing-remitting multiple sclerosis.
Norton Neuroscience Institute enrolled first patient in national ACCLAIM study.
Title: JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2
Sponsor: Biogen Idec Inc.
Physician Investigator(s): Robert S. Tillett Jr., M.D., MS certified specialist
Purpose: To identify multiple sclerosis patients who have a specific antibody in their blood against the JC virus (JCV). The purpose of STRATIFY-2 is to gather more information about how many MS patients being treated with Tysabri or who are considering beginning Tysabri have the JCV antibody in their blood and to better understand whether antibodies to JCV may be used to predict whether a patient is at higher or lower risk for developing progressive multifocal leukoencephalopathy (PML).
Title: Genetic Evaluation of Natalizumab-Treated Patients with Progressive Multifocal Leukoencephalopathy (PML)
Sponsor: Biogen Idec Inc.
Physician Investigator(s): Robert S. Tillett Jr., M.D., MS certified specialist
Purpose: The purpose of this study is to examine the possible genetic susceptibility to PML in patients who develop PML while being treated with Tysabri (natalizumab).
Title: TYGRIS: Tysabri Global Observational Program in Safety
Sponsor: Biogen Idec
Principal Investigator: Robert S. Tillett Jr., M.D., MS certified specialist
Purpose: The purpose of this study is to determine the incidence and pattern of serious infections, malignancies and other serious adverse events in patients with MS treated with Tysabri (natalizumab).
Title: A Study of Ocrelizumab in Comparison with Interferon Beta-1a (Rebif) in Patients with Relapsing Multiple Sclerosis
Sponsor: Hoffman-LaRoche
Principal Investigator: Robert S. Tillett Jr., M.D., MS certified specialist
Purpose: This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with Rebif (interferon beta-1a) in patients with relapsing multiple sclerosis. Patients will be randomized to receive either in group A, ocrelizumab 600 mg intravenously (IV) every 24 weeks plus Rebif placebo subcutaneously (sc) three times weekly or, in group B, Rebif 8.8 mcg (weeks 1+2)/22 mcg (weeks 3+4)/44 mcg (week 5 and following) sc three times weekly plus ocrelizumab placebo IV every 24 weeks. Anticipated time on study treatment is 96 weeks.
Learn More about Multiple Sclerosis |
